Research

Cellular

Atherogenic dyslipidemias are a major contributor to ASCVD within the CKM framework.

Recognize and address dyslipidemias in patients with obesity to mitigate cardiovascular disease risk.

StrongSupportsmedium confidence
Atherogenic dyslipidemias are a hallmark of high-risk obesity phenotypes and a major contributor to ASCVD within the CKM framework.
Hun Jee Choe et al. · European Journal of Clinical Investigation · 2025

Why this rating

The claim is supported by a comprehensive review of existing literature.

Source

Obesity phenotypes and atherogenic dyslipidemias

Hun Jee Choe et al. · European Journal of Clinical Investigation · 2025

DOI 10.1111/eci.70151

reviewCited 4×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →